NASD · Healthcare · Biotechnology · USA
Protagonist Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Protagonist Therapeutics develops investigational medicines across inflammation and immunology, hematology, and metabolic diseases. The company's pipeline includes Icotyde, licensed to Johnson & Johnson for psoriasis treatment; Rusfertide, co-developed with Takeda for polycythemia vera; and PN-881, an oral antagonist for immune-mediated skin conditions, alongside obesity programs.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Protagonist Therapeutics Inc stock.
Overvalued: intrinsic value $18.21 per share, market price $134.44, margin of safety -638.2% (as of 2026-10-19).
Discounting its cash flows at 10.8% (average of 3 methods) values the shares at $18.21; the price of $134.44 is 638% above that value, and 69% of that value comes from beyond year five.
Leak Score: 43/100 on 10 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
107 more in this industry show a wider margin of safety.
PTGX is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 10.8% (average of 3 methods) values the shares at $18.21; the price of $134.44 is 638% above that value, and 69% of that value comes from beyond year five.
$18.21 per share (as of the 2026-10-19 close), against a market price of $134.44. That is a margin of safety of -638.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
43 out of 100, which we rate "On Watch", on 10 of 12 value investing signals.